和誉-B(02256.HK)：FGFR2/3抑制剂ABSK061获FDA授予罕见儿科疾病药物资格认定

Core Viewpoint - The company, He Yu-B (02256.HK), announced that its subsidiary, Shanghai He Yu Biomedical Technology Co., Ltd., has received FDA designation for its self-developed selective oral small molecule FGFR2/3 inhibitor, ABSK061, for the treatment of achondroplasia, a rare pediatric disease [1] Group 1 - The FDA has granted the rare pediatric disease designation to ABSK061, indicating its potential significance in treating achondroplasia [1] - The drug is a high-selectivity, oral small molecule FGFR2/3 inhibitor, showcasing the company's innovative approach in drug development [1]